

Ontario Drug Benefit Formulary/Comparative Drug Index

Edition 43

Summary of Changes – December 2022
Effective December 21, 2022

Drug Programs Policy and Strategy Branch
Health Programs and Delivery Division
Ministry of Health

[Visit Formulary Downloads: Edition 43](#)

Table of Contents

New Single Source Products.....	3
New Multi-Source Products.....	4
New Off-Formulary Interchangeable (OFI) Products.....	7
Temporary Benefits.....	8
Addition to Limited Use Criteria.....	9
Manufacturer Name Changes.....	11
Product Brand Name Changes.....	12
Drug Benefit Price (DBP) Changes.....	13
Discontinued Products.....	15
Delisted Products.....	16

New Single Source Products

Generic Name: LEVETIRACETAM

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02490447	PDP-Levetiracetam	100mg/mL	Oral Sol	PEN	0.8142/mL

Reason For Use Code and Clinical Criteria

Code 640

For patients unable to swallow or tolerate oral solid dosage forms and who are using this as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.

LU Authorization Period: 1 year

Code 705

As adjunctive therapy in the treatment of seizure disorders in pediatric patients (less than 18 years of age) where control by other listed anticonvulsants has been unsatisfactory and where the appropriate dose cannot be achieved using listed solid oral levetiracetam dosage formats.

LU Authorization Period: 1 year

Generic Name: INSULIN GLARGINE

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02526441	Semglee	100U/mL	Inj Sol-3mL Pref Pen	BGP	12.7668/Pref Pen

New Multi-Source Products

Where applicable, please consult the respective brand reference product's drug profile on the ODB e-Formulary for the details of the Limited Use (LU) code and criteria, and/or any associated Therapeutic Notes (TN).

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02530708	Apixaban	2.5mg	Tab	SIV	0.4084

(Interchangeable with Eliquis DIN 02377233 – LU)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
09858180	Apixaban	2.5mg	Tab	SIV	0.4084

(Interchangeable with Eliquis PIN 09857463 – LU)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02530716	Apixaban	5mg	Tab	SIV	0.4084

(Interchangeable with Eliquis DIN 02397714 – LU)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02375311	Apo-Brimonidine-Timop	0.2% & 0.5%	Oph Sol-10mL Pk	APX	34.9350

(Interchangeable with Combigan PIN 09857298 – LU)

New Multi-Source Products (Continued)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02526557	Apo-Fluticasone HFA	125mcg/Metered Dose	Inh-120 Dose Pk	APX	23.4100

(Interchangeable with Flovent HFA – GB)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02508656	Apo-Sitagliptin Malate	25mg	Tab	APX	1.6394
02508664	Apo-Sitagliptin Malate	50mg	Tab	APX	1.6394
02508672	Apo-Sitagliptin Malate	100mg	Tab	APX	1.6394

(Interchangeable with Januvia – GB)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02509415	Apo-Sitagliptin Malate/Metformin Hydrochloride	50mg & 500mg	Tab	APX	0.8893
02509423	Apo-Sitagliptin Malate/Metformin Hydrochloride	50mg & 850mg	Tab	APX	0.8893
02509431	Apo-Sitagliptin Malate/Metformin Hydrochloride	50mg & 1000mg	Tab	APX	0.8893

(Interchangeable with Janumet – GB)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02506270	Apo-Sitagliptin/Metformin XR	50mg & 500mg	ER Tab	APX	0.8893
02506289	Apo-Sitagliptin/Metformin XR	50mg & 1000mg	ER Tab	APX	0.8893
02506297	Apo-Sitagliptin/Metformin XR	100mg & 1000mg	ER Tab	APX	1.7785

(Interchangeable with Janumet XR – GB)

New Multi-Source Products (Continued)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02527154	Entecavir	0.5mg	Tab	SAI	4.4000

(Interchangeable with Baraclude – LU)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02510731	Jamp Cloxacillin	250mg	Cap	JPC	0.2141
02510758	Jamp Cloxacillin	500mg	Cap	JPC	0.4045

(Interchangeable with Orbenin – GB)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02530694	M-Amoxi Clav	400mg/5mL & 57mg/5mL	Pd for Susp	MAT	0.2386/mL

(Interchangeable with Clavulin – GB)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02529769	M-Ticagrelor	90mg	Tab	MAT	0.7920

(Interchangeable with Brilinta – LU)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP
02522519	PRZ-Amlodipine	5mg	Tab	PRZ	0.1343
02522527	PRZ-Amlodipine	10mg	Tab	PRZ	0.1993

(Interchangeable with Norvasc – GB)

New Off-Formulary Interchangeable (OFI) Products

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	Unit Cost
02482622	Apo-Ticagrelor	60mg	Tab	APX	1.2844

(Interchangeable with Brilinta)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	Unit Cost
02529750	M-Ticagrelor	60mg	Tab	MAT	1.2844

(Interchangeable with Brilinta)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	Unit Cost
02520931	NRA-Tadalafil	5mg	Tab	NRA	3.6471
02520966	NRA-Tadalafil	20mg	Tab	NRA	12.3575

(Interchangeable with Cialis)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	Unit Cost
02531526	PMS-Pirfenidone	267mg	Tab	PMS	6.7120
02531534	PMS-Pirfenidone	801mg	Tab	PMS	20.1360

(Interchangeable with Esbriet Tab DIN 02464489 and DIN 02464500)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	Unit Cost
02526875	Sandoz Ambrisentan Tablets	5mg	Tab	SDZ	106.3288
02526883	Sandoz Ambrisentan Tablets	10mg	Tab	SDZ	106.3288

(Interchangeable with Volibris)

Temporary Benefits

DIN/PIN	Brand Name	Strength	Dosage Form	Generic Name	Mfr	DBP
02523019	Propylthiouracil Tablets	50mg	Tab	PROPYLTHIOURACIL	PHB	0.5000

Addition to Limited Use Criteria

Addition to all strengths of OSELTAMIVIR PHOSPHATE

Addition is in bold

Code 639

For treatment of individuals **during the 2022–2023 influenza season** who are at high risk* of complications from influenza infection and have either:

1. Laboratory-confirmed influenza A or influenza B infection;
- OR
2. Illness consistent with influenza A or influenza B infection

* High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:

- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)

Revisions of Limited Use Criteria (Continued)

- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples

Maximum dosage: 75mg twice daily for 5 days

Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits

Note: Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.

LU Authorization Period: 6 months

Manufacturer Name Changes

DIN/PIN	Brand Name	Strength	Dosage Form	Current Mfr	New Mfr
09857386	Botox	50U/Vial	Pd Inj-50U Vial Pk	ALL	ABV
01981501	Botox	100U/Vial	Pd Inj-100U Vial Pk	ALL	ABV
09857387	Botox	200U/Vial	Pd Inj-200U Vial Pk	ALL	ABV
02212307	Ceftin	125mg/5mL	Susp	GSK	SDZ
02306085	Valcyte	50mg/mL	Pd for Oral Sol- 100mL Pk	HLR	CHE
02245777	Valcyte	450mg	Tab	HLR	CHE

Product Brand Name Changes

DIN/PIN	Current Brand Name	New Brand Name	Strength	Dosage Form	MFR
09854215	Nutren Junior	Nutren Junior 1.0	1kcal/mL	Liq-250mL Pk	NES
09854223	Nutren Junior Fibre	Nutren Junior Fibre 1.0	1kcal/mL	Liq-250mL Pk	NES
09857427	Resource Diabetic	Resource Diabetic 1.05	1.06kcal/mL	Liq-250mL Pk	NES

Drug Benefit Price (DBP) Changes

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP/Unit Price
02439654	Act Bupropion XL	150mg	ER Tab	ACV	0.2926
02439662	Act Bupropion XL	300mg	ER Tab	ACV	0.5853
02234503	Apo-Terazosin	2mg	Tab	APX	0.5005
02244126	Dovobet	50mcg/g & 0.5mg/g	Oint	LEO	1.8458/g
02319012	Dovobet Gel	50mcg/g & 0.5mg/g	Top Gel	LEO	1.8417/g
01976133	Dovonex	50mcg/g	Oint	LEO	1.0518/g
02270811	Finacea	15%	Top Gel	LEO	0.7380/g
00586668	Fucidin	2%	Cr	LEO	0.9433/g
00586676	Fucidin	2%	Oint	LEO	0.9433/g
09857367	Innohep	2500IU/0.25mL	Inj Pref Syr	LEO	6.4095
02358158	Innohep	3500IU/0.35mL	Inj Pref Syr	LEO	8.9633
02358166	Innohep	4500IU/0.45mL	Inj Pref Syr	LEO	11.5276
02429462	Innohep	8000IU/0.4mL	Inj Pref Syr	LEO	19.9363
02231478	Innohep	10000IU/0.5mL	Inj Pref Syr	LEO	26.1426
02429470	Innohep	12000IU/0.6mL	Inj Pref Syr	LEO	31.4003
02358174	Innohep	14000IU/0.7mL	Inj Pref Syr	LEO	36.6333
02429489	Innohep	16000IU/0.8mL	Inj Pref Syr	LEO	41.8675
02358182	Innohep	18000IU/0.9mL	Inj Pref Syr	LEO	47.0952
02167840	Innohep	10000IU/mL	Inj-2mL Pk	LEO	48.3880
02229515	Innohep	20000IU/mL	Inj-2mL Pk	LEO	103.2082
01923439	Palafer	60mg/mL	O/L	GSK	0.0981/mL
02503123	PMS-Fluticasone HFA	125mcg/Metered Dose	Inh-120 Dose Pk	PMS	23.4100
02380900	PMS-Nabilone	0.5mg	Cap	PMS	1.8886
02243519	PMS-Terazosin	2mg	Tab	PMS	0.5005

Drug Benefit Price (DBP) Changes (Continued)

DIN/PIN	Product Name	Strength	Dosage Form	Mfr	DBP/Unit Price
02244148	Protopic	0.1%	Oint	LEO	3.0899/g
02244149	Protopic	0.03%	Oint	LEO	2.8884/g
02475804	Taro-Bupropion XL	150mg	ER Tab	SPC	0.2926
02475812	Taro-Bupropion XL	300mg	ER Tab	SPC	0.5853
02492598	Taro-Ticagrelor	90mg	Tab	TAR	0.7920
00337765	Teva-Cloxacillin	250mg	Cap	TEV	0.2141
00337773	Teva-Cloxacillin	500mg	Cap	TEV	0.4045
02384884	Teva-Nabilone	0.5mg	Cap	TEV	1.8886

Discontinued Products

(Some products will remain on Formulary for six months to facilitate depletion of supply)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr
02242903	Enbrel	25mg/Vial	Inj Pd-Vial Pk	IMU
00629324	Novo-Profen	200mg	Tab	NOP
02437945	Pantoprazole	40mg	Ent Tab	PMS
02379171	PMS-Esomeprazole DR Cap	40mg	DR Cap	PMS

Delisted Products

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr
02237618	Adalat XL	20mg	ER Tab	BAY
02155990	Adalat XL	60mg	ER Tab	BAY
02242965	Avelox	400mg	Tab	BAY
01984845	Bonefos	400mg	Cap	BAY
02155958	Cipro	250mg	Tab	BAY
02155966	Cipro	500mg	Tab	BAY
02155974	Cipro	750mg	Tab	BAY
02247916	Cipro XL	500mg	ER Tab	BAY
02251787	Cipro XL	1000mg	ER Tab	BAY
02393581	Co Nabilone	0.5mg	Cap	COB
02382075	Mylan-Bupropion XL	150mg	ER Tab	MYL
02382083	Mylan-Bupropion XL	300mg	ER Tab	MYL
02399377	PMS-Atorvastatin	10mg	Tab	PMS
02399385	PMS-Atorvastatin	20mg	Tab	PMS
02399393	PMS-Atorvastatin	40mg	Tab	PMS
02399407	PMS-Atorvastatin	80mg	Tab	PMS
02477173	PMS-Atorvastatin	80mg	Tab	PMS
02429160	Sandoz Alendronate/Cholecalciferol	70mg & 140mcg	Tab	SDZ
02230806	Teva-Terazosin	2mg	Tab	TEV

